Tiziana Life Sciences confident of advancing drug development pipeline
Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) said it is confident that it is well positioned to advance its drug development programs “to their next respective value inflection points”.
Final results on Tuesday showed cash of £48.2mln in the bank at the end of December, after a year when the company made a loss before tax of £21.8mln as R&D and operating costs increased as it continued to progress a pipeline of drugs to treat rare cancers and autoimmune and inflammatory diseases.
One of these is an investigational new technology to treat COVID-19 infections by using a nasal delivery system to directly deliver monoclonal antibodies (mAbs) into the lungs.
Preclinical studies are ongoing and Tiziana said it hopes to begin a trial investigating the delivery of an anti-IL-6R mAb to the lungs using a portable nasal delivery system.
“This treatment could be useful for different variants of COVID-19 and we are exploring these in an upcoming preclinical study,” it said.
Tiziana also plans to develop subcutaneous delivery of anti_IL-6R mAb for treatment of acute respiratory distress syndrome (ARDS) and other inflammatory conditions.
On Foralumab, the company’s lead product candidate in immunology, Phase 2 studies are due to shortly begin with orally administration of the drug for Crohn’s Disease and nasally administered Foralumab for progressive multiple sclerosis.
For Milciclib, where intellectual property has been in-licensed from Nerviano Medical Sciences, a Phase 2b clinical trial is planned in people with hepatocellular carcinoma (HCC) with Milciclib in combination with a Tyrosine kinase inhibitors such as Regorafenib or Sorafenib.
The company said it also intends to evaluate Milciclib in combination with standard of care treatments for other solid tumour indications.
An agreement was recently made with Takanawa Japan for a strategic business development plan to identify a clinical partner for further clinical development of Milciclib for treatment in advanced HCC patients.
“We believe the positive clinical activity in advanced HCC and other cancers warrant immediate further development in Japan and other Asian countries where the prevalence of this cancer is relatively high, and the current available therapies are not entirely satisfactory,” the company said.
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/949822/tiziana-life-sciences-confident-of-advancing-drug-development-pipeline-949822.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).